|
05 Jan 2023 |
IntoCell Enters into Development and License Option Agreement with ADC Therapeutics
|
|
05 Jan 2023 |
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
|
|
05 Jan 2023 |
Nirsevimab US regulatory submission accepted for the prevention of RSV lower respiratory tract disease in infants and children up to age 24 months
|
|
04 Jan 2023 |
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Posi
|
|
04 Jan 2023 |
Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009
|
|
04 Jan 2023 |
NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates
|
|
04 Jan 2023 |
Arugula Sciences Announces Company Launch with FDA Phase 1 Approval for Osteoarthritis Therapy
|
|
04 Jan 2023 |
Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS Franchise
|
|
04 Jan 2023 |
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
|
|
04 Jan 2023 |
Belharra Therapeutics Announces Broad Collaboration with Genentech to Discover and Develop Novel Medicines Across Multiple Therapeutic Areas
|
|
04 Jan 2023 |
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
|
|
04 Jan 2023 |
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
|
|
04 Jan 2023 |
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
|
|
04 Jan 2023 |
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
|
|
04 Jan 2023 |
Orano Med Starts Phase I Trial With Alpha Radioligand Therapy 212Pb-GRPR in Patients With Solid Tumors
|
|
04 Jan 2023 |
ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Ca
|
|
03 Jan 2023 |
OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
|
|
03 Jan 2023 |
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
|
|
03 Jan 2023 |
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany
|
|
03 Jan 2023 |
HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B
|
